New cell shot aims to tame stubborn nerve attacks
NCT ID NCT07265206
First seen Jan 10, 2026 · Last updated Apr 24, 2026 · Updated 11 times
Summary
This early-stage study tests a new cell treatment called HY001N for people with severe autoimmune diseases that attack the brain, spinal cord, or nerves and have not responded to standard therapies. The main goal is to check if the treatment is safe and tolerable in 15 adults aged 18 to 75. Researchers will also look for early signs that it might help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROLOGICAL AUTOIMMUNE DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.